Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis an…
An institutional-grade, numbers-driven thesis on ADPT — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Adaptive Biotechnologies Corporation (ADPT) 67/100 with a 12-month base-case forecast of $24.38 — -1.5% versus the current price of $24.74. Adaptive Biotechnologies Corporation trades at $24.74 in the Healthcare sector, with a market capitalisation of $3.96B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for ADPT is $24.38, implying -1.5% versus the current price. The model's 12-month scenario range runs from $30.63 (bear) to $49.14 (bull), with a base case of $37.74.
On the fundamentals, Adaptive Biotechnologies shows a P/E of -60.7, trailing revenue of $277.0M, revenue growth of +54.8% YoY. This page also tracks ADPT's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ADPT currently carries a TradersQuant composite score of 67/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $24.38 implies -1.5% from $24.74. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for ADPT is $24.38, about -1.5% versus the latest price of $24.74. Consensus is based on 17 analysts.
TradersQuant's 12-month model forecast for ADPT is a base case of $37.74, ranging from $30.63 (bear) to $49.14 (bull), an expected return of +52.6%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ADPT over the next 12 months is $37.74 in the base case (bear $30.63, bull $49.14), versus today's price of $24.74. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ADPT — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ADPT's fair value at $24.38, implying -1.5% of expected upside versus the current price.
Adaptive Biotechnologies does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
